贝瑞基因(000710) - 2025 Q2 - 季度业绩预告

Berry Genomics 2025 Semi-Annual Performance Forecast Interpretation This report interprets Berry Genomics' 2025 semi-annual performance forecast, detailing core financial projections, reasons for performance changes, and audit-related disclosures Core Performance Forecast Data The company anticipates a loss for the first half of 2025, with net profit attributable to shareholders projected to be a loss of RMB 22 million to RMB 33 million, a shift from a profit of RMB 9.2628 million in the same period last year Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: 22.00 - 33.00 million RMB | Profit: 9.2628 million RMB | | Net Profit Excluding Non-Recurring Gains/Losses | Loss: 24.00 - 35.00 million RMB | Profit: 9.49 million RMB | | Basic Earnings Per Share | Loss: 0.0622 - 0.0933 RMB/share | Profit: 0.0262 RMB/share | Analysis of Performance Changes The decline in performance is primarily attributed to external market conditions and internal strategic investments, including increased R&D and domestic substitution efforts, partially offset by non-recurring income - Company's operating revenue and profitability decreased year-on-year due to industry cyclicality and intensified market competition[4] - The company increased R&D investment, with its GENOisi intelligent agent project reaching cooperation intentions with multiple hospitals, while steadily advancing domestic substitution transformation, which is expected to improve future cost structure[4] - During the reporting period, the company recorded approximately RMB 2 million in non-recurring income, primarily from the disposal of Prenetics shares[4] Audit and Risk Disclosure The company emphasizes that this performance forecast data is a preliminary estimate by the finance department and has not been audited, with final data subject to the official semi-annual report - This performance forecast data is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[3][5] - The company has pre-communicated the performance forecast with the accounting firm, and there are no significant disagreements[3]